Paycom Software, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Paycom Software, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $150.33M | Feb 14, 2019 |
| FY2018 | Sep 30, 2018 | $133.29M | Feb 14, 2019 |
| FY2018 | Jun 30, 2018 | $128.80M | Feb 14, 2019 |
| FY2018 | Mar 31, 2018 | $153.92M | Feb 14, 2019 |
| FY2018 | Dec 31, 2017 | $114.03M | Feb 14, 2019 |
| FY2018 | Sep 30, 2017 | $101.29M | Feb 14, 2019 |
| FY2018 | Jun 30, 2017 | $98.23M | Feb 14, 2019 |
| FY2018 | Mar 31, 2017 | $119.51M | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $87.81M | Feb 14, 2018 |
| FY2017 | Sep 30, 2016 | $77.33M | Feb 14, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.05B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.88B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.69B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $1.38B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.06B | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $220.95M | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | $196.53M | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | $181.59M | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | $242.37M | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | $193.41M | Feb 18, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.71B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.55B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.42B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $1.16B | Feb 20, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $453.40M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $502.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $340.80M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $281.40M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $195.96M | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $24.37M | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | $27.48M | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | $28.59M | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | $63.02M | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | $45.38M | Feb 18, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $567.20M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $634.30M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $451.30M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $378.70M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $253.57M | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $36.25M | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | $34.04M | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | $26.58M | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | $89.26M | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | $60.29M | Feb 18, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $283.40M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $242.60M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $199.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $148.30M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $118.43M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $90.24M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $73.08M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $46.25M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $30.43M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $20.97M | Feb 14, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.14B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $914.30M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $966.10M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $783.80M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $640.07M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $531.77M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $401.70M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $301.86M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $231.31M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $173.34M | Feb 14, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $678.90M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $533.90M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $485.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $365.10M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $319.36M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $227.21M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $224.26M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $184.82M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $130.15M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $98.82M | Feb 14, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $270.90M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $192.90M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $192.60M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $132.70M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $120.69M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $94.10M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $92.93M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $59.91M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $59.39M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $43.81M | Feb 14, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.60B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $5.86B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $4.20B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $3.90B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $3.22B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $2.61B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $2.49B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $1.52B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $1.55B | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $1.08B | Feb 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.87B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $4.28B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $2.89B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $2.72B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $2.32B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $1.95B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $1.96B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $1.19B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $1.27B | Feb 14, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.73B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.58B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.30B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $1.18B | Feb 20, 2025 |
| FY2024 | Dec 31, 2021 | $893.70M | Feb 20, 2025 |
| FY2023 | Dec 31, 2020 | $655.64M | Feb 15, 2024 |
| FY2022 | Dec 31, 2019 | $526.63M | Feb 16, 2023 |
| FY2021 | Dec 31, 2018 | $334.75M | Feb 17, 2022 |
| FY2020 | Dec 31, 2017 | $281.25M | Feb 18, 2021 |
| FY2019 | Dec 31, 2016 | $205.69M | Feb 13, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.90M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $51.90M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $51.90M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $51.89M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $51.89M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $51.89M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $51.89M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $51.89M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $51.89M | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $51.89M | Feb 14, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.26B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.89B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.47B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.20B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $915.58M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $719.62M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $576.17M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $395.59M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $258.53M | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $70.45M | Feb 14, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $370.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $402.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $294.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $400.70M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $277.98M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $151.71M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $133.67M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $45.72M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $46.08M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $60.16M | Feb 14, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $29.00M | Feb 16, 2023 |
| FY2022 | Dec 31, 2021 | $29.16M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $30.89M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $32.63M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $34.39M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $35.30M | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $29.82M | Feb 14, 2018 |
| FY2016 | Dec 31, 2015 | $25.74M | Feb 21, 2017 |
| FY2015 | Dec 31, 2014 | $26.98M | Feb 22, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 8 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | 1 | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 18, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 8 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | 1 | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 18, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 54.80M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 55.90M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 56.50M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | 57.87M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | 58.01M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | 57.74M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | 57.66M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | 57.28M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | 57.79M | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | 57.33M | Feb 14, 2018 |